229 related articles for article (PubMed ID: 27758856)
1. Novel Antibody for the Treatment of Transthyretin Amyloidosis.
Hosoi A; Su Y; Torikai M; Jono H; Ishikawa D; Soejima K; Higuchi H; Guo J; Ueda M; Suenaga G; Motokawa H; Ikeda T; Senju S; Nakashima T; Ando Y
J Biol Chem; 2016 Nov; 291(48):25096-25105. PubMed ID: 27758856
[TBL] [Abstract][Full Text] [Related]
2. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
[TBL] [Abstract][Full Text] [Related]
3. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.
Obayashi K; Tasaki M; Jono H; Ueda M; Shinriki S; Misumi Y; Yamashita T; Oshima T; Nakamura T; Ikemizu S; Anan I; Suhr O; Ando Y
Clin Chim Acta; 2013 Apr; 419():127-31. PubMed ID: 23462670
[TBL] [Abstract][Full Text] [Related]
4. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
5. Antibody therapy for familial amyloidotic polyneuropathy.
Su Y; Jono H; Torikai M; Hosoi A; Soejima K; Guo J; Tasaki M; Misumi Y; Ueda M; Shinriki S; Shono M; Obayashi K; Nakashima T; Sugawara K; Ando Y
Amyloid; 2012 Jun; 19 Suppl 1():45-6. PubMed ID: 22506915
[TBL] [Abstract][Full Text] [Related]
6. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant.
Terazaki H; Ando Y; Fernandes R; Yamamura K; Maeda S; Saraiva MJ
Lab Invest; 2006 Jan; 86(1):23-31. PubMed ID: 16357867
[TBL] [Abstract][Full Text] [Related]
7. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
8. Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy.
Palha JA; Moreira P; Olofsson A; Lundgren E; Saraiva MJ
J Mol Med (Berl); 2001; 78(12):703-7. PubMed ID: 11434723
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.
Ferreira N; Saraiva MJ; Almeida MR
PLoS One; 2012; 7(1):e29933. PubMed ID: 22253829
[TBL] [Abstract][Full Text] [Related]
10. [Pathogenesis and therapy for transthyretin related amyloidosis].
Ando Y; Jono H
Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
[TBL] [Abstract][Full Text] [Related]
11. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S
Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467
[TBL] [Abstract][Full Text] [Related]
12. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models.
Cardoso I; Martins D; Ribeiro T; Merlini G; Saraiva MJ
J Transl Med; 2010 Jul; 8():74. PubMed ID: 20673327
[TBL] [Abstract][Full Text] [Related]
13. Potential use of glucuronylglucosyl-β-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy.
Jono H; Anno T; Motoyama K; Misumi Y; Tasaki M; Oshima T; Mori Y; Mizuguchi M; Ueda M; Shinriki S; Shono M; Obayashi K; Arima H; Ando Y
Amyloid; 2012 Jun; 19 Suppl 1():50-2. PubMed ID: 22620966
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Potential of Polyamidoamine Dendrimer for Amyloidogenic Transthyretin Amyloidosis.
Inoue M; Ueda M; Higashi T; Anno T; Fujisawa K; Motoyama K; Mizuguchi M; Ando Y; Jono H; Arima H
ACS Chem Neurosci; 2019 May; 10(5):2584-2590. PubMed ID: 30912637
[TBL] [Abstract][Full Text] [Related]
15. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
16. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.
Ueda M; Misumi Y; Mizuguchi M; Nakamura M; Yamashita T; Sekijima Y; Ota K; Shinriki S; Jono H; Ikeda S; Suhr OB; Ando Y
Clin Chem; 2009 Jun; 55(6):1223-7. PubMed ID: 19372189
[TBL] [Abstract][Full Text] [Related]
17. Presence of autoantibody against ATTR Val30Met after sequential liver transplantation.
Ando Y; Terazaki H; Haraoka K; Tajiri T; Nakamura M; Obayashi K; Misumi S; Shoji S; Hata K; Nakagawa K; Ishizaki T; Uemoto S; Inomata Y; Tanaka K; Okabe H
Transplantation; 2002 Mar; 73(5):751-5. PubMed ID: 11907422
[TBL] [Abstract][Full Text] [Related]
18. Loss of functional albumin triggers acceleration of transthyretin amyloid fibril formation in familial amyloidotic polyneuropathy.
Kugimiya T; Jono H; Saito S; Maruyama T; Kadowaki D; Misumi Y; Hoshii Y; Tasaki M; Su Y; Ueda M; Obayashi K; Shono M; Otagiri M; Ando Y
Lab Invest; 2011 Aug; 91(8):1219-28. PubMed ID: 21537325
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
Hayashi Y; Jono H
Biol Pharm Bull; 2018; 41(12):1737-1744. PubMed ID: 30504675
[TBL] [Abstract][Full Text] [Related]
20. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms.
Ueda M; Ando Y; Hakamata Y; Nakamura M; Yamashita T; Obayashi K; Himeno S; Inoue S; Sato Y; Kaneko T; Takamune N; Misumi S; Shoji S; Uchino M; Kobayashi E
Biochem Biophys Res Commun; 2007 Jan; 352(2):299-304. PubMed ID: 17126291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
